Literature DB >> 27815438

The Acute-on-Chronic Liver Failure Syndrome, or When the Innate Immune System Goes Astray.

Joan Clària1,2, Vicente Arroyo3, Richard Moreau4.   

Abstract

The acute-on-chronic liver failure (ACLF) syndrome is characterized by acute decompensation of cirrhosis, organ failure, and high 28-d mortality. ACLF displays key features of systemic inflammation and its poor outcome is closely associated with exacerbated systemic inflammatory responses. In this review, we describe the prevailing characteristics of systemic inflammation in patients with decompensated cirrhosis and ACLF, with special emphasis on the principal features of the cytokine storm the mechanisms underlying this intense systemic inflammatory response (i.e., presence of circulating pathogen- and damage-associated molecular patterns), and their implication in tissue and organ damage in this condition.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27815438     DOI: 10.4049/jimmunol.1600818

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  32 in total

1.  Patients With Acute on Chronic Liver Failure Grade 3 Have Greater 14-Day Waitlist Mortality Than Status-1a Patients.

Authors:  Vinay Sundaram; Parth Shah; Robert J Wong; Constantine J Karvellas; Brett E Fortune; Nadim Mahmud; Alexander Kuo; Rajiv Jalan
Journal:  Hepatology       Date:  2019-05-17       Impact factor: 17.425

2.  Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice.

Authors:  Xiaogang Xiang; Dechun Feng; Seonghwan Hwang; Tianyi Ren; Xiaolin Wang; Eszter Trojnar; Csaba Matyas; Ruidong Mo; Dabao Shang; Yong He; Wonhyo Seo; Vijay H Shah; Pal Pacher; Qing Xie; Bin Gao
Journal:  J Hepatol       Date:  2019-11-29       Impact factor: 25.083

3.  A nomogram to predict survival in patients with acute-on-chronic hepatitis B liver failure after liver transplantation.

Authors:  Liang Chen; Jiebin Zhang; Tongyu Lu; Jianye Cai; Jun Zheng; Jia Yao; Shuhong Yi; Hua Li; Guihua Chen; Hui Zhao; Yingcai Zhang; Yang Yang
Journal:  Ann Transl Med       Date:  2021-04

Review 4.  Disruption of the gut-liver axis in the pathogenesis of acute-on-chronic liver failure.

Authors:  Tao Zhang; Kewei Sun; Ya Wang; Lei Huang; Ren Lang; Wei Jiang
Journal:  Eur J Gastroenterol Hepatol       Date:  2018-02       Impact factor: 2.586

5.  Acute-on-Chronic Liver Failure: From Basic Research to Clinical Applications.

Authors:  En-Qiang Chen; Tetsuro Shimakami; Yu-Chen Fan; Paolo Angeli
Journal:  Can J Gastroenterol Hepatol       Date:  2018-10-08

6.  A Double-Blind, Randomized Placebo-Controlled Trial of Probiotic Lactobacillus casei Shirota in Stable Cirrhotic Patients.

Authors:  Jane Macnaughtan; Francesco Figorilli; Elisabet García-López; Haw Lu; Helen Jones; Rohit Sawhney; Kaori Suzuki; Sarah Fairclough; Joanne Marsden; Alba Moratella; I Jane Cox; Linda Thomas; Nathan Davies; Roger Williams; Raj Mookerjee; Gavin Wright; Rajiv Jalan
Journal:  Nutrients       Date:  2020-06-02       Impact factor: 5.717

7.  Deletion of caveolin-1 attenuates LPS/GalN-induced acute liver injury in mice.

Authors:  Tsung-Huang Tsai; Kabik Tam; Shu-Fen Chen; Jun-Yang Liou; Yi-Chen Tsai; Yen-Ming Lee; Tai-Yu Huang; Song-Kun Shyue
Journal:  J Cell Mol Med       Date:  2018-08-22       Impact factor: 5.310

8.  Altered PGE2-EP2 is associated with an excessive immune response in HBV-related acute-on-chronic liver failure.

Authors:  Yunyun Wang; Chao Chen; Jinjin Qi; Fengtian Wu; Jun Guan; Zhi Chen; Haihong Zhu
Journal:  J Transl Med       Date:  2019-03-19       Impact factor: 5.531

Review 9.  Regulation of Monocyte-Macrophage Responses in Cirrhosis-Role of Innate Immune Programming and Checkpoint Receptors.

Authors:  Antonio Riva; Gautam Mehta
Journal:  Front Immunol       Date:  2019-02-05       Impact factor: 7.561

10.  Latent Cytomegalovirus Reactivation in Patients With Liver Failure: A 10-Year Retrospective Case-Control Study, 2011-2020.

Authors:  Qingluan Yang; Zhe Zhou; Xuefang Yang; Yuming Chen; Aiping Liu; Bingyan Zhang; Lingyun Shao; Jianming Zheng; Wenhong Zhang
Journal:  Front Cell Infect Microbiol       Date:  2021-05-10       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.